Date:7/7/2009

further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which may affect the future use of orBec(R) for gastrointestinal GVHD include the risks that: the FDA's requirement that DOR conduct additional clinical trials to demonstrate the safety and efficacy of orBec(R) will take a significant amount of time and money to complete and positive results leading to regulatory approval cannot be assumed; DOR is dependent on the expertise, effort, priorities and contractual obligations of third parties in the clinical trials, manufacturing, marketing, sales and distribution of its products; orBec(R) may not gain market acceptance if it is eventually approved by the FDA; and others may develop technologies or products superior to orBec(R). These and other factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, DOR's most recent reports on Forms 10-Q and 10-K. Unless required by law, DOR assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

'/>"/>

SOURCE DOR BioPharma, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine news :

1. AlphaRx and Gaia BioPharma Report Positive Efficacy Results in a Pre-Clinical Trial of GAI-122 Injectable Nano-emulsion for Post-operative Delirium
2. Helix Biopharma Corp. Begins Trading on the OTCQX International Market Listing as HXBPF
3. Sinobiopharma Receives Trademark Approval and Authentication From Chinese Government For Its Tai Drug Series
4. Keryx Biopharmaceuticals Inc. Regains Compliance With NASDAQ Listing Requirements
5. AlphaRx and Gaia BioPharma Provide GAI-122 Development Update
6. PDL BioPharma Announces Record Date for October 1 Dividend Payment
7. Keryx Biopharmaceuticals, Inc. Receives Extension for Nasdaq Listing Compliance
8. SAFE-BioPharma Webinar Featuring ARX's Digital Signatures Combined with Microsoft SharePoint for Bio-Pharma industry
9. Prix Galien USA Now Accepting Nominations for Premiere Biopharmaceutical Industry Award
10. The Sage Group Widens Strategic Role to Assist HemispherX Biopharma in Pandemic Influenza Initiatives as Pacific Rim/Japan Treatment/Prevention Programs Accelerate
11. SAFE-BioPharma Webinar Featuring ARX's Digital Signature Solution and Adobe LiveCycle Combined Solution